These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24847649)

  • 21. Resistance to direct antiviral agents in patients with hepatitis C virus infection.
    Sarrazin C; Zeuzem S
    Gastroenterology; 2010 Feb; 138(2):447-62. PubMed ID: 20006612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of interferon resistance in hepatitis C.
    Gretch D
    Lancet; 2001 Nov; 358(9294):1662-4. PubMed ID: 11728538
    [No Abstract]   [Full Text] [Related]  

  • 23. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.
    Susser S; Vermehren J; Forestier N; Welker MW; Grigorian N; Füller C; Perner D; Zeuzem S; Sarrazin C
    J Clin Virol; 2011 Dec; 52(4):321-7. PubMed ID: 21924672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis.
    Zhang H; Quadeer AA; McKay MR
    Nat Commun; 2023 Nov; 14(1):7457. PubMed ID: 37978179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Forthcoming challenges in the management of direct-acting antiviral agents (DAAs) for hepatitis C.
    Bruno R; Cima S; Maiocchi L; Sacchi P
    Dig Liver Dis; 2011 May; 43(5):337-44. PubMed ID: 20980211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
    Thomson JA; Perni RB
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
    Wyles DL
    J Infect Dis; 2013 Mar; 207 Suppl 1():S33-9. PubMed ID: 23390303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance.
    Götte M
    Curr Opin Virol; 2012 Oct; 2(5):644-50. PubMed ID: 22964133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.
    Susser S; Welsch C; Wang Y; Zettler M; Domingues FS; Karey U; Hughes E; Ralston R; Tong X; Herrmann E; Zeuzem S; Sarrazin C
    Hepatology; 2009 Dec; 50(6):1709-18. PubMed ID: 19787809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
    Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
    Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
    Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
    Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New protease inhibitors for HCV--help is on the way.
    Fusco DN; Chung RT
    J Hepatol; 2011 Jun; 54(6):1087-9. PubMed ID: 21232563
    [No Abstract]   [Full Text] [Related]  

  • 36. [A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].
    Chen ZW; Hu P; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):165-9. PubMed ID: 27095757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C: An unsuspected drug target.
    Murray CL; Rice CM
    Nature; 2010 May; 465(7294):42-4. PubMed ID: 20445618
    [No Abstract]   [Full Text] [Related]  

  • 38. Hepatitis C: move over interferon.
    Garber K
    Nat Biotechnol; 2011 Nov; 29(11):963-6. PubMed ID: 22068526
    [No Abstract]   [Full Text] [Related]  

  • 39. The emerging field of HCV drug resistance.
    Koev G; Kati W
    Expert Opin Investig Drugs; 2008 Mar; 17(3):303-19. PubMed ID: 18321230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Predictive factors of response to Direct Acting Antivirals therapy Drug resistance hepatitis C virus].
    Suda G; Yamasaki K; Sakamoto N
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():189-92. PubMed ID: 26845928
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.